These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15510514)

  • 21. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
    Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
    Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
    Traverso CE; Ropo A; Papadia M; Uusitalo H
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.
    Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa Y
    J Ocul Pharmacol Ther; 2001 Feb; 17(1):19-25. PubMed ID: 11322634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients.
    Kondo N; Sawada A; Yamamoto T; Taniguchi T
    Jpn J Ophthalmol; 2006; 50(1):20-4. PubMed ID: 16453183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone.
    Susanna R; Medeiros FA; Vessani RM; Giampani J; Borges AS; Jordão ML
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):401-10. PubMed ID: 15650515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma.
    Haneda M; Shirato S; Maruyama K; Ohno Y
    Jpn J Ophthalmol; 2006; 50(1):33-7. PubMed ID: 16453185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
    Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
    Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of replacement of timolol-pilocarpine with latanoprost in pseudoexfoliation glaucoma.
    Bojić L; Mandić Z; Novak-Laus K; Sonicki Z; Karelović D
    Coll Antropol; 2003 Dec; 27(2):729-34. PubMed ID: 14746165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of latanoprost additive therapy on uncontrolled glaucoma.
    Bayer A; Tas A; Sobaci G; Henderer JD
    Ophthalmologica; 2002; 216(6):443-8. PubMed ID: 12566890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies.
    Konstas AG; Bányai L; Blask KD; Väth J; Kozobolis VP; Trüb PR; Tsironi S; Maloutas S; Teus MA; Stewart WC
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):375-82. PubMed ID: 15650512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma.
    Aung T; Chan YH; Chew PT;
    Ophthalmology; 2005 Feb; 112(2):267-71. PubMed ID: 15691562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.
    Shin DH; McCracken MS; Bendel RE; Pearlman R; Juzych MS; Hughes BA; Schulz LL; Kim C; Baek NH
    Ophthalmology; 1999 Feb; 106(2):386-90. PubMed ID: 9951495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial.
    Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
    Br J Ophthalmol; 2008 Mar; 92(3):332-6. PubMed ID: 18211927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.